Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 12Gynecologic 7Breast 3Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Breast Neoplasms 3Breast Neoplasms, Male 1

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Imiquimod × Breast × Clear all
NCT01421017 2021-11-18

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NYU Langone Health

Phase 1/2 Completed
31 enrolled 11 charts
Breast

Breast Neoplasms

NCT00821964 2018-01-02

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

University of Washington

Phase 2 Completed
15 enrolled 11 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00899574 2015-12-07

Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases

NYU Langone Health

Phase 2 Completed
10 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡